Atezolizumab Combo Approved for PD-L1-positive TNBC.
The FDA approved atezolizumab plus nab-paclitaxel for patients with locally advanced or metastatic triple-negative breast tumors expressing PD-L1. The combination is the first immunotherapy regimen to earn marketing authorization for any type of breast cancer.